Filing Date

08/28/99

12/08/98

03/02/99

10/03/96

11/24/98

08/26/97

03/27/00

Substitute Form PTO-1449PP 1 2 2007:S Department of Commerce (Modified)

Patient and Trademark Office

Attorney's Docket No. 17170-002002

January 21, 2004

Application No. 10/762,444

Applicant

U.S. Patent Documents

Publication

Filing Date

Gerardo Castillo et al.

Group Art Unit Unknown

List of Patents and Publications for Applicant's Information Disclosure Statement

Document

(37 CFR §1.98(b))

Desig.

P

Q

R

S

T

U

٧

6,037,327

6,264,994

6,297,281

6,340,783

6,346,280

6,432,636

6,563,016

Examiner

Date Initial Number Patentee **Subclass** If Appropriate ID Class 08/15/02 Castillo et al. 08/22/01 どん Α 2002/0111309 514 12 2, C В 2002/0168753 11/14/02 Castillo et al. 435 11/30/01 226 С 2002/0197692 12/26/02 Castillo et al. 435 184 11/02/01 ಒ D 2003/0013648 01/16/03 Castillo et al. 12 09/24/01 514 27 E 2003/0017998 01/23/03 Snow et al. 514 02/15/02 5,643,562 2-F 07/01/97 Kisilevsky et al. 424 78.31 03/15/95 2.0 Kuznicki et al. G 5,681,569 10/28/97 195 424 11/06/95 ZuF H 5,719,191 02/17/98 Maclean et al. 514 648 02/21/97 I 5,731,313 03/24/98 Suarato et al. 255 07/24/95 514 2. J 5,747,517 05/05/98 Panetta et al. 514 369 09/11/96 K 5,767,126 06/16/98 297 Marchbanks 514 1018/94 L 08/18/97 5,869,469 02/09/99 Szarek 514 120 24 M 5,958,883 09/28/99 Snow 514 16 06/05/95 ZF N 5,972,956 10/26/99 Hays et al. 514 297 04/29/98 O 5,981,168 11/09/99 Reiner 435 4 05/15/98

Castillo et al.

Castillo et al.

Castillo et al.

Maresh et al.

Snow et al.

Snow

De Lassauniere et al.

| | Foreign Patent Documents or Published Foreign Patent Applications | | | | | | | |
|------------------|---|--------------------|---------------------|-----------------------------|-------|----------|--|---------------|
| Examiner Initial | Desig. ID ⊀ £ | Document Number | Publication Date | Country or Patent Office | Class | Subclass | | slation No |
| 2.F | w _s e | 00/12102 | 03/09/00 | PCT | | | | |
| 2.6 | x x | 10245342 | 09/14/98 | Љ | | | | X+ |

| Examiner | Signature |
|----------|-----------|

24

Zahnf Faz

03/14/00

07/24/01

10/02/01

01/22/02

02/12/02

08/13/02

05/13/02

Date Considered

2/10/06

514

424

514

800

424

435

800

23

725

589

12

725

6

12

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Substitute Form PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office | | | | 1 '' | | | | | |
|---|--|-----------|-------------|------------------------------|-----------------------------------|-------------|---------------------------|---------|--|
| List of Pa | List of Patents and Publications for Applicant's | | | Applicant Gerardo Castill | Applicant Gerardo Castillo et al. | | | | |
| Information Disclosure Statement | | | | Filing Date January 21, 200 | Filing Date January 21, 2004 | | Group Art Unit Unknown | | |
| (37 CFR §1.98 | | | | | | | | | |
| | | | | ublished Foreign | Patent / | Application | | | |
| Examiner | Desig. | Document | Publication | Country or | | 0.5.1 | | slation | |
| Initial | ID | Number | Date | Patent Office | Class | Subclass | Yes | No_ | |
| ZIF | Y | 01/49281 | 07/12/01 | PCT | | | | | |
| 24 | Z | 01/49307 | 07/12/01 | PCT | | | | | |
| 5-F | AA | 0 659 418 | 12/19/94 | EP | | | | | |
| ZF | AB | 1 014 996 | 05/28/03 | EP | | | | | |
| ZiF | AC | 1-151514 | 06/14/89 | JР | | | | X+ | |
| ZIF | AD | 97/46664 | 12/11/97 | PCT | | | | | |
| 24 | AE | 98/08381 | 03/05/98 | PCT | | | | | |
| ZF | AF | 98/09653 | 03/12/98 | PCT | | | | X+ | |
| 25 | AG | 98/24646 | 06/11/98 | PCT | | | | | |
| O:F | АН | 98/34646 | 08/13/98 | PCT | | | | | |
| ZIF | ΑI | 98/39653 | 09/11/98 | PCT | | | | | |
| 2.4 | AJ | 98/51302 | 11/19/98 | PCT | | | | | |

| | Other D | ocuments (include Author, Title, Date, and Place of Publication) |
|----------|---------|---|
| Examiner | Desig. | |
| Initial | ID | Document |
| Zif | AK AK | Arai et al, "Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/α-synuclein," <i>Neurosc. Lett.</i> 259:83-86 (1999) |
| ZIF | АЬ | Barner et al., "Donepezil Use in Alzheimer Disease", Ann. Pharmacotherapy, 32:70-77 (1998) |
| 25 | AM | Benson et al., "Serum Amyloid A Protein In Amyloidosis, Rheumatic, And Neoplastic Diseases", Arth. Rheum., 22:36-42 (1979) |
| sit | AN | Castillo et al. "Sulfate content and specific glycosaminoglycan backbone of perlecan are critical of perlecan't enhancement of islet amyloid polypeptide (Amylin) Fibril formation." Diabetes, 47: 612-620, (1998 |
| 25 | AO/P | Castillo et al., "Laminin inhibition of beta-amyloid protein (A beta) fibrillogenesis and identification of an A beta binding site localized to the globular domain repeat on the laminin a chain", J. Neurosci. Res., 62(3):451-462 (2000) |
| SIF | APX | Castillo et al., "Novel purification and detailed characterization of perlecan isolated from the Engelbreth-Holm-Swarm tumor for use in an animal model of fibrillar A beta amyloid persistence in brain", J. Biochem., 120(2):433-444 (1996) |
| ZIF | AQ | Castillo et al., "Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability", J. Neurochem., 69(6):2452-2465 (1997) |

| Examiner Signature | Zahrf Faz | Date Considered | 2/10/06 | | | | |
|---|--|-----------------|---------|--|--|--|--|
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | | | | | | |
| conformance and not con | conformance and not considered. Include conv of this form with next communication to applicant | | | | | | |

| Substitute Fon (Modified) | n PTO-1449 | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17170-002002 | Application No. 10/762,444 | | | |
|------------------------------|---|--|---|---|--|--|--|
| l ist of P | atents an | d Publications for Applicant's | Applicant Gerardo Castillo et al. | | | | |
| | | n Disclosure Statement | Filing Date | Group Art Unit | | | |
| | | | January 21, 2004 | Unknown | | | |
| (37 CFR §1.98 | (b)) | | 3, · | | | | |
| | | ocuments (include Author, 1 | Title Date and Place of | f Publication) | | | |
| Examiner | Desig. | The later of the l | The, Date, and I lace o | i i ubilcation, | | | |
| Initial | . ID | | Document | | | | |
| ZF | AR | Castillo et al., "Structure and metaboli the isolated rat glomerulus", Biochem. | ism of multiple heparan sulphate Biophys. Acta, 1136(2):119-12 | e proteoglycans synthesized by 8 (1992) | | | |
| 7 - | | Castillo et al., "Subunit structure of bo | ovine ESF (extracellular-matrix | stabilizing factor(s)). A | | | |
| 2 F | ASX | chondroitin sulfate proteoglycan with FEBS Lett., 318(3):292-296 (1993) | homology to human I alpha i (ir | nter-alp trypsin inhibitors)", | | | |
| 2. F | | Castillo et al., "Sulfate content and spe | | | | | |
| - F | AT/ | perlecan's enhancement of islet amylo 620 (1998) | id polypeptide (amylin) fibril fo | rmation", <i>Diabetes</i> , 47(4):612- | | | |
| ZIF | AU/ | Castillo et al., "The sulfate moieties of | f glycosaminoglycans are critica | l for the enhancement beta- | | | |
| 1 | AU/ | amyloid protein fibril formation", J. N | | | | | |
| z. F | AV -f | Certified English Translation of Lewy | in Handbuch der Neurologie, L | ewandowski, Ed., Springer, | | | |
| | | 20tim, pp. 320 303, 1312 | | | | | |
| 2, F | AWE | Conway et al., "Accelerated in vitro fi | | nuclein linked to early-onset | | | |
| | | 1 I II KINSON GISCUSC, Walare Wea. 4.1516-1520, (1556) | | | | | |
| ZIF | AXI | Cooper et al. "Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients." <i>Proc. Natl. Acad. Sci. USA</i> , 84:8629-8632, (1987) | | | | | |
| ZF | AY# | Crutcher et al., "Cellular and molecula (1993) | | ase", Hippocampus, 3:271-287 | | | |
| 2.F | AZ. | Cutler et al., "Tacrine in Alzheimer's Disease", N. Engl. J. Med., 328:808-810 (1993) | | | | | |
| | | Derwent abstract for Japanese Patent A | | | | | |
| Zif | BA ★ | treating and preventing nervous diseases - contains carboxylic acid, pref. gallic or pyrogallol-4- | | | | | |
| ١ | | carboxylic acid, esp. useful for alzhein | | | | | |
| 2.F | вв≉ | Derwent WPI Acc. No. 12134240 (cit nerve cell toxicity of beta-amyoloid pr | | | | | |
| Zcf | BC★ | Flood et al. "Amnestic effects in mice | of four synthetic peptides homo | logous to amyloid B protein | | | |
| | | from patients wit alzheimer disease." | Proc. Natl. Acad. Sci. USA, 88:3 | 363-3366 (1991) | | | |
| ZL | вр≭ | Flood et al. "An amyloid β-protein fra | gment, A β [12-18], equipotently | impairs post-training memory | | | |
| | BD & | processing when injected into different limbic system structures." Brain Research 663:271-276 (1994). | | | | | |
| 7 | | E 1 100 C 11 101 111 | ogenesis of Alzheimer A heta n | entides with selected | | | |
| Zif | BE⊁ | substitution of charged residues", J. M | ol. Biol., 244(1):64-73 (1994) | ephaes with selected | | | |
| | | Fukuchi et al., "Increased expression of | of beta-amyloid protein precurso | r and microtubule-associated | | | |
| Sit | BF≭ | protein tau during the differentiation o | f murine embryonal carcinoma | cells", J. Neurochem., | | | |
| | | 58(5):1863-1873 (1992) | | | | | |
| 2.F 2.F 2.F | BG X | Games et al. "Alzheimer-type neuopathology in transgenic mice overexpressing V717F B-amyloid | | | | | |
| | | Govin et al. "A New Form of Amelia | | *** | | | |
| ZiF | BH Ceyjo et al., "A New Form of Amyloid Protein Associated with Chronic Hemodialysis was | | | | | | |
| | Identified as β2-microglobulin", Biochem. Biophys. Res. Comm., 129:701-706 (1985) BIX Geyjo et al., "β2-microglobulin: A new form of amyloid protein associated with chronic | | | | | | |
| C.F-1 | віЖ | hemodialysis", Kidney Int., 30:385-39 | 0 (1986) | iated with emonic | | | |
| | | | - () | | | | |

| Examiner Signature | Zohlfon | Date Considered 2/10/06 | | | |
|--|---------|-------------------------|--|--|--|
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant | | | | | |

| Substitute For (Modified) | Form PTO-1449 U.S. Department of Comme Patent and Trademark Off | | Attomey's Docket No. 17170-002002 | Application No. 10/762,444 | | | |
|------------------------------|--|--|--|-------------------------------|--|--|--|
| | | | | | | | |
| | | | Applicant Gerardo Castillo et al. | | | | |
| | | d Publications for Applicant's | | | | | |
| [n | iformation | n Disclosure Statement | Filing Date | Group Art Unit | | | |
| | | | January 21, 2004 | Unknown | | | |
| (37 CFR §1.98 | (b)) | | | | | | |
| | | ocuments (include Author, 1 | Fitle, Date, and Place of | f Publication) | | | |
| Examiner Initial | Desig. ID | | Document | | | | |
| | | Glenner et al. "Alzheimer's Disease: In | | and Characterization of a | | | |
| 2.5 | BJ⊁ | Novel Cerebrovascular Amyloid Prote 120(3): 885-890 (1984) | | | | | |
| | вк≭ | Grundke-Ibal et al., "Abnormal phosp alzheimer cytoskeletal pathology", Pre | | | | | |
| | BL | Haass et al. "The swedish mutation ca with in the secretory pathway." Nature | | | | | |
| | вмХ | Harada et al., "Human Amyloid Prote Cytochem., 19:1-15 (1971) | | | | | |
| | BN | Hardy et al., "Framing β-amyloid", No | | | | | |
| | вож | Harrigan et al. "Beta Amyloid is Neur Aging, 16(5): 779-789, (1995) | otoxic in Hippocampal Slice Cu | ltures," The Neurobiology of | | | |
| | ВРҗ | Hart et al., "Overproduction of perleca Pathol., 194(2):262-269 (2001) | an core protein in cultured cells | and transgenic mice", J. | | | |
| | во⊁ | Hashimoto et al., "Human recombinar | Hashimoto et al., "Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease," Brain Res. 799:301-306, (1998) | | | | |
| | BR | Hertel et al., "Inhibition of the electron prevents J-amyloid-induced toxicity," | static interaction between J-amy | | | | |
| | BS | Hsiao et al. "Age-related CNS Disorder alsheimer amyloid precursor proteins. | er and early death in transgenic l | FVB/N mice overexpressing | | | |
| | BT _y L | Johnson et al., "Biology of Disease. Is the Pancreatic Islets and Potential Rol | let Amyloid Polypeptide: Mecha | anisms of Amyloidogenesis in | | | |
| | BUX | Johnson et al., "Islet Amyloid, Islet-A | | | | | |
| | BVX | 321:513-518 (1989) Jucker et al., "Age-related deposition of the state of the stat | | ial in brains of C57BL/6 | | | |
| | | mice", Neuroscience, 60(4):875-889 (Kamei et al., "Amyloidosis Associated | | hritus" Acta Path Jan | | | |
| | BW ⋡ | 32:123-133 (1982) | | • | | | |
| | вх≰ | Kitaguchi et al. "Novel Precursor of A Inhibitory Activity," Nature, 331:530- | -532, (1988) | | | | |
| | ву≭ | Klunk et al., "Quantiying Amyloid B- Spectrophotometric Assay," Analytica | Peptide (AB) Aggregation Using al Biochemistry, 266:66-76 (1999) | g the Congo Red-AB (CR-AB) | | | |
| | BZ⋠ | Kosik et al., "Microtubule-associated filaments in Alzheimer disease", Proc | protein tau is a major antigenic c | component of paired helical | | | |
| | CA 🛧 | Krüger, Rejko et al., "Ala30Pro mutat Nature Genet. 18:106-108, (1998) | | | | | |
| | СВ≯ | Lee et al., "A68: A Major Subunit of I Tau", Science, 251:675-678 (1991) | Paired Helical Filaments and Der | rivatized Forms of Normal | | | |
| | cc¥ | Levine. "Thioflavine T interaction wit | h synthetic alzheimer's disease E | B-amyloid peptides: Detection | | | |
| | CCA | of amyloid aggregation in solution." F | Protein Science, 2:404-410, (199 | 3) | | | |
| ZIF | CD3K | Lewy in Handbuch der Neurologie, Le | ewandowski, Ed., Springer, Berl | in, pp. 920-933, 1912 | | | |

| Examiner Signature | Zohnf For | Date Considered | 2/10/06 | | |
|--|-----------|-----------------|---------|--|--|
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant | | | | | |

Sheet 5 of 5 present polication No. 0/762,444

| Substitute For (Modified) | rm PTO-1449 U.S. Department of Commerc Patent and Trademark Office | | Attomey's Docket No. 17170-002002 | Application No. 10/762,444 | | |
|---------------------------|---|--|--------------------------------------|---------------------------------|--|--|
| l ist of P | atents an | d Publications for Applicant's | Applicant Gerardo Castillo et al. | | | |
| | | n Disclosure Statement | Filing Date | Group Art Unit | | |
| | | | January 21, 2004 | Unknown | | |
| (37 CFR §1.98 | 3(b)) | | | | | |
| | Other D | ocuments (include Author, 1 | litle, Date, and Place o | f Publication) | | |
| Examiner | Desig. | | | | | |
| Initial | ID | | Document | | | |
| 2.F | CE | Mandybur et al. "Cerebral Amyloid A Journal of Neuropathology and Exper | rimental Neurology, 45(1): 79-90 |), (1986). | | |
| } | ~= / | Maresh et al., "Detection and quantita | | | | |
| | CFX | aged hippocampus by competitive rev 67(3):1132-1144 (1996) | erse transcription-polymerase ch | nain reaction", J. Neurochem., | | |
| | CG≰ | Masters et al. "Amyloid Plaque Core I | | nd Down Syndrome," <i>Proc.</i> | | |
| | 4,00 | Natl. Acad. Sci. USA 82:4245-4249 (1 | | | | |
| | СНЖ | McAdam et al., "Association of Amyl Recurrent neutrophil Leucocytosis in | | | | |
| | CI# | Metaxis et al., "Familial Mediterranea | | | | |
| | `` | Miller et al., "Localization of perlecan | | | | |
| | C1 / | vitro and to microglia/macrophages fo | | d protein into rodent | | |
| | | hippocampus", Gila, 21(2):228-243 (1 | oid recursor protein associated a | eith havaditam, alahaimada | | |
| | CK ∦ | Murrell et al. "A mutation in the amyloid recursor protein associated with hereditary alzheimer's disease." Science, 254: 97-99 (1991) | | | | |
| | CL | Nahri et al. "Both familial Parkinson's Biol. Chem. 274:9843-9846 (1999) | • | | | |
| | CMP | Naiki et al. "Kinetic analysis of amylo 65(1):104-110, (1991) | id Fibril polymerization in vitro | " Laboratory Investigation, | | |
| | CN | Naiki, H. and K. Nakakuki, "First-ord vitro," Laboratory investigation, 74(2 | | β-amyloid fibril extension in | | |
| | cox | Niwano et al., "Inhibitory action of an XII)," J. Lab. Clin. Med. 125:251-6 (1 | nyloid precursor protein against | human Hageman factor (factor | | |
| | • | Pardridge et al. "Amyloid Angiopathy | | Acid Composition and Partial | | |
| İ | CP ★ | Sequence of a 4,200-Dalton Peptid Iso | plated from Cortical Microvessel | s," Journal of Neurochemisty, | | |
| | 1 | 17(3): 137 (1701) | | | | |
| | cox | Pike et al. "In Vitro Aging of β-Amylo Brain Research, 563:311-314, (1991) | oid Protein Cause Peptide Aggre | gation and Neurotoxity," | | |
| | CR-g(| Pike et al. "Structure-Activity Analyse to Aggregation and Neurotoxicity," Jo | es of β-Amyloid Peptides: Contr | ibutions of the β25-35 Region | | |
| | | Pollanen et al., "Pathology and Biolog | ry of the Lewy Body." Journal of | f Neuropathology and | | |
| | cs* | Experimental Neurology, 52(3):183-19 | 91 (1993) | | | |
| | стж | Polymeropoulos et al., "Mutation in the disease," Science 276:2045-2047 (199 | | d in families with parkinson's | | |
| | CU ⊀ | Ponte et al. "A New A4 Amyloid mR1 | NA Contains a Domain Homolog | gous to Serine Proteinase | | |
| | | Inhibitors," <i>Nature</i> , 311:525-527, (198) Puchtler, H. et al., "On the binding of | | l of Histochomistry | | |
| | cvX | Cytochemistry 10:355-364 (1962) | congo rea by amyloid," Journa | oj risiocnemistry ana | | |
| | | Rogers et al., "Long-term efficacy and | safety of donepezil in the treatm | nent of Alzheimer's disease: | | |
| ZUF | CM. | an interim analysis of the results of a I | JS multicentre open label extens | | | |
| 1 | * | Neuropsychopharmacol., 8:67-75 (199 | 98) | | | |

| Examiner Signature | Zahuf For | Date Considered 2 /10 /06 | | | |
|---|-----------|---------------------------|--|--|--|
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | | | | |
| conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| | | <u> </u> | | | | | | |
|--|---|----------|-------------|--|---|-------|----------|----------------|
| Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Tradesings Office | | | | | Attorney's Docket No. Application No. 17170-002002 10/762,444 | | | |
| ln In | Substitute Form PTO-1449 U.S. Department of Commerce Patent and Traces new Office 17170-002002 Information Disclosure Statement by Applicant (Use several sheets if access at) (Use Several sheets if access at) | | | | | | | |
| (37 CFR §1.98 | (Use several sheets if necessary) AUS 2 (37 CFR §1.98(b)) | | | | Filing Date Group Art Unit Vanuary 21, 2004 1614 | | | 1 |
| | U.S. Patent Documents | | | | | | | |
| U.S. 42 arent Documents | | | | | | | | |
| Examiner | Desig. | Document | Publication | | | | | Filing Date |
| Initial | ID d | Number | Date | | Patentee | Class | Subclass | If Appropriate |
| | | | | | | | | |

| Foreign Patent Documents or Published Foreign Patent Applications | | | | | | | | |
|---|--------------|--------------------|---------------------|-----------------------------|-------|----------|--------------|--------------|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Trans Yes | lation No |
| 2LF | A | 00/57707 | 10/05/00 | PCT | | | | |
| 1 | В | 02/062422 | 08/15/02 | PCT | | | | |
| | С | 02/076381 | 10/03/02 | PCT | | | | |
| erc | D | 99/09999 | 03/04/99 | PCT | | | | |

| (| Other D | ocuments (include Author, Title, Date, and Place of Publication) | | | | |
|---|--|---|--|--|--|--|
| Examiner | Desig. | | | | | |
| Initial | ID. | Document | | | | |
| 2,5 | E | "Progress Report on Alzheimers Disease," The National Institute on Aging, National Institutes of Health, 1997. | | | | |
| | F | Baumann et al, "A simple isolation method for the major catechins in green tea using high-speed countercurrent chromatography," J. Natural Prod. 64:353-355, (2001) | | | | |
| | G | Braquet et al. "Ethnopharmacology and the Development of Natural PAF Antagonists as Therapeutic Agents," Journal of Ethnopharmacology, 32:135-139, (1991) | | | | |
| | Н | Calis et al, "Flavonoid, Iridoid, and Lignan Glycosides from Putoria calabrica," J. Nat. Prod. 64:961-964, (2001) | | | | |
| | I | Clark et al, "Islet Amyloid, Increased A-Cells, Reduced B-Cells and Exocrine Fibrosis: Quantitative Changes in The Pancreas in Type 2 Diabetes," <i>Diabetes Res.</i> 9:151-159, (1988) | | | | |
| | J | Czochanska et al, "Direct Proof of a Homogeneous Polyflavan-3-ol Structure for Polymeric Proanthocyanidins," J.C. S. Chem. Comm. pp. 375-377, (1979) | | | | |
| | Derwent World Patents Index, Dialog File Number 351 Accession Number 12134240; JP K 10245342A "Agent for Reducing Nerve Cell Toxicity of Beta-Amyloid Protein - Contains Tell Polyphenol" | | | | | |
| | L | Ferreira et al, "Tetrahedron Report Number 308: Diversity of Structure and Function in Oligomer Flavanoid," <i>Tetrahedron</i> 48:1743-1803, (1992) | | | | |
| | М | Fletcher et al, "Plant Proanthocyanidins. Part 3. Conformational and Configurational Studies of Natural Procyanidins," JCS Perkin 1:1628-1637, (1977) | | | | |
| N Gujer et al, "Glucosylated Flavonoids and Other Phenolic Compounds From Sorghum," Phytochemistry 25:1431-1436 (1986) | | | | | | |
| | 0 | Hashimoto et al, "Tannins and related Compounds. XC. 8-C-Ascorbyl (-) -Epigallocatechin 3-)-Gallate and novel dimeric Flavan-3-ols, Oolonghomobisflavans A and B from Oolong tea.", Chem Pharm. Bull. 37(12) 3255-3263 (1989) | | | | |
| | P | Hemingway et al, "Linkage Isomerism in Trimeric and Polymeric 2,3-cis-Procyanidins," J. Chem. Soc. Perkins Trans. 1:1209-1216 (1982) | | | | |
| 215 | Q | Ho et al. "Phytochemicals in Teas and Rosemary and Their Cancer-Preventive Properties," ACS Symp. Ser. (Food Phytochemicals for Cancer Prevention II) vol. 547, pp. 2-19 1994. | | | | |
| Examiner Sign | Z | Ehrl Fay Date Considered 2/10/06 | | | | |
| EXAMINER: In next communic | nitials citation ation to app | n considered. Draw line through citation if not in conformance and not considered. Include copy of this form with licant. | | | | |

| | Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. Application No. 17170-002002 10/762,444 | | |
|---|--|--|---|----------------|--|
| | Information Discl by App | | Applicant Gerardo Castillo et al. | | |
| ļ | (Use several sheets if necessary) | | Filing Date | Group Art Unit | |
| i | (37 CFR 61 98(b)) | | January 21, 2004 | 1614 | |

| | Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
|------------------|---|---|--|--|--|--|
| Examiner Initial | Desig. ID | Document | | | | |
| 2.F | R | Hsiao et al. "Age-related CNS Disorder and early death in transgenic FVB/N mice overexpressing alsheimer amyloid precursor proteins." <i>Neuron</i> , vol. 15, 1203-1218, Nov., 1995. | | | | |
| | AB | Ishimaru et al, "Flavan-2-ol and Procyanidin Glycosides from Quercus Miyagii," Phytochemistry 26:1167-1170, (1987) | | | | |
| | AC | Jain et al. "Antiinflammatory Effects of an Ayurvedic Preparation, Brahmi Rasayan, in Rodents," Indian Journal of Experimental Biology, 32:633-636 (1994) | | | | |
| | AD | Jones et al, "The Condensed Tannins of Pasture Legume Species," <i>Photochemistry</i> , 15:1407-1409 (1976) | | | | |
| | AE | Kashiwada et al, "Tannins and Related Compounds. XCIII." Occurrce of Enantiomeric Proanthocyanidins in the Leguminosae Plants, Cassia fistula L. and C.javanica L.," Chem. Pharm. Bull. 38:888-893 (1990) | | | | |
| | AF | Kim et al, "Neuroprotective Constituents from Hedyotis diffusa," J. Nat. Prods. 64:75-78, (2001) | | | | |
| | AG | Latimer et al. "71. Inhibitors of Amyloid-β Aggregation: Dimeric Catechols Inhibit Aggregation and Deposition of Aβ," American Chemical Society 221 st National Meeting, San Diego, CA April 1-5, 2001 (MEDI 071) [posted on 03/23/01] | | | | |
| | АН | Levine. "Thioflavine T interacton with amyloid B-sheet structures. "Amyloid: Int. J. Exp. Clin. Invest. 2:1-6, (1995) | | | | |
| | AI | Lorenzo et al, "Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus," Nature 368:756-760, (1994) | | | | |
| | AJ | Matthews et al, "Method for estimation of Proanthocyanidins based on their acid depolymerization in the presence of nucleophiles," J. Agric. Food Chem. 45:1195-1201, (1997) | | | | |
| | AK | Mattice et al, "Molecular weight averages and ¹³ C NMR intensities provide evidence for branching in proanthocyanidin polymers," <i>Phytochem.</i> 23(6):1309-1311, (1984) | | | | |
| | AL | Morimoto et al, "Tannins and Related Compounds. LXI." Isolation and Structure of Novel Bi- and Triflavanoids from the leaves of Cassia fistula L.," Chem. Pharma. Bull. 36:39-47, (1988) | | | | |
| | AM | Nonaka et al, "Tannins and Related Compound. XV.") A New Class of Dimeric Flavan-3-ol Gallates, Theasinensins A and B, and Proanthocyanidin Gallates from Green Tea Leaf. (1)," Chem. Pharm. Bull. 31:3906-3914, (1983) | | | | |
| | AN | Patent Abstracts of Japan citing Japanese Patent 10-245342 published September 14, 1998, "Agent for reducing neural toxicity of beta-amyoloid protein" | | | | |
| | AO | Porter et al, "Isolation of three naturally occurring O-β-glucopyranodsides of procyanidin polymers," Phytochemistry 24:567-569, (1985) | | | | |
| | AP | Porter, L.J, "Flavans and proanthocyanidins," Chapter 2 in Flavans and proanthocyanidins Advances in Research since 1986, J B Harborne (Ed.) London: Chapman and Hall pp. 23-55, 1994 | | | | |
| | AQ | Porter, J.J, "Flavans and proanthocyanidins," Chapter 2 in <i>The FlavanoidsAdvances in Research since 1980</i> , JB Harborne (Ed.), London: Chapman and Hall, pp. 21-62, 1988 | | | | |
| | AR | Prieur et al, "Oligomeric and polymeric procyanidins from grape seeds," <i>Phyochem.</i> 36:781-784, 1994 | | | | |
| | AS | Sang et al, "Iridoid Glycosides from the leaves of Morinda citrifolia,": J. Nat. Prod. 64:799-800 (2001) | | | | |
| 2.F | AT | Santos-Buelga, C. and A. Scalbert, "Proanthocyanidins and tannin-like compounds - nature, occurrence, dietry intake and effects on nutrition and health," <i>J. Sci Food Agri.</i> 80: 1094-1117, (2000) | | | | |

| Examiner Signature | Zohnf | Fan | Date Considered | 2/10/06 |
|---|-----------------------------------|---------------------|-------------------------|---|
| EXAMINER: Initials cit next communication to | ation considered. Draw line three | ough citation if no | ot in conformance and n | ot considered. Include copy of this form with |

| Substitute Form PTO-1449 (Modified) | | | Attorney's Docket No. Application No. 17170-002002 10/762,444 | | |
|---|------------------|-----------------------------------|---|--|--|
| | losure Statement | Applicant Gerardo Castillo et al. | | | |
| (Use several sheets if necessary) (37 CFR §1.98(b)) | | Filing Date January 21, 2004 | Group Art Unit 1614 | | |

| | Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
|------------|---|---|--|--|--|--|
| Examiner | Desig. | | | | | |
| Initial ID | | Document | | | | |
| ZF | AU Snow. "Proteoplycans in the pathogenesis of alzheimer's disease and other amyloide Neurobiology of Aging, 10:481-497, (1989) | | | | | |
| | | Stappenbeck et al., "80. Inhibitors of Amyloid-β Aggregation: Histidine Residues in Aβ Play a | | | | |
| } | AV | Crucial Role in Aggregation," American Chemical Society 221st National Meeting, San Diego, CA | | | | |
| | | April 1-5, 2001 (MEDI 080) [posted on 03/23/01] | | | | |
| 1 1 | AW | Steinberg. "Uncaria Tomentosa (cat's Claw) A wondrous herb from the peruvian rain forest." | | | | |
| <u></u> | AW | Townsend Letter for Doctors-pp, 442-443, may 1994. | | | | |
| | | Sugita-Konishi et al., "Epigallocatechin gallate and gallocatechin gallate in green tea catechins | | | | |
| 1 1 | AX | inhibit extracellular release of Vero toxin from enterohemorrhagic Escherichia coli O157:H7," | | | | |
| | | Biochimica et Biophysica Acta 1472:42-50 (1999) | | | | |
| | AY | Tamaoka et al. "Amyloid B protein 1-42/43(AB 1-42/43) in crebellar diffuse plaques: enzyme- | | | | |
| | | linked immunosorbent assay and immunocytochemical study." Brain Research 67:151-156 (1995) | | | | |
| | | Tamaoka et al. "Biochemical evedence for the long tail form of amyloid B protein as a seed | | | | |
| | ΑZ | molecule in cerebral deposits of alzheimer's disease." Biochemical and biophysical research | | | | |
| | | communications, 205(1): 834-842, (1994) | | | | |
| | BA | Thompson et al, "Plant Proanthocyanidins. Part 1. Introduction; the Isolation, Structure, and | | | | |
| <u> </u> | | Distribution in Nature of Plant Procyanidins," J. Chem. Soc. Perkins Trans. 1: 1387-1399 (1972) | | | | |
|] \ | | Tückmantel, "Studies in Polyphenol Chemistry and Bioactivity. 1. Preparation of Building Blocks | | | | |
| | BB | from (+)-Catechin. Procyanidin Formation. Synthesis of the Cancer Cell Growth Inhibitor, 3-O- | | | | |
| | | Galloyl-(2R,3R)-epicatechin-4β,8-[3-O-Galloyl-(2R,3R)-epicatechin]," J. Am. Chem. Soc. | | | | |
| | | 121:12073-12081 (1999) | | | | |
| | BC | Wirth et al. "Pharmacologically active procyanidines from the bark of Uncaria tomentosa." | | | | |
| - | | Phytomedicine, vol. 4 (3), pp. 265-266, 1997. | | | | |
| ZIF | BD | Zhang et al, "Potentillanin, A Biflavanoid and a procyanidin glycoside from potentilla viscosa," | | | | |
| | | Phytochemistry 27:3277-3280, (1988) | | | | |

| Examiner Signature | Zahn | | Date Considered | 2/10/06 |
|----------------------------------|-------------------------|---------------------------|----------------------|--|
| EXAMINER: Initials citati | on considered. Draw lin | ne through citation if no | t in conformance and | not considered. Include copy of this form with |
| next communication to ap | | - | | •• |

Substitute Disclosure Form (PTO-1449)